Plecanatide

Overview

Plecanatide is a peptide medication marketed as Trulance and used to treat certain chronic digestive conditions. It is an analog of uroguanylin, a naturally occurring peptide that helps regulate fluid balance and movement within the intestine. By mimicking this natural signal, plecanatide aims to relieve constipation-related symptoms.

It is approved for two related conditions: chronic idiopathic constipation, meaning persistent constipation without an identifiable underlying cause, and irritable bowel syndrome with constipation, often abbreviated IBS-C. Both involve infrequent or difficult bowel movements and, in the case of IBS-C, accompanying abdominal discomfort.

Plecanatide is taken as an oral tablet and works locally within the gut. It belongs to a small class of guanylate cyclase-C agonists, which represent a targeted approach to constipation that differs from traditional laxatives by acting on a specific receptor pathway in the intestinal lining.

How it works

Plecanatide activates a receptor called guanylate cyclase-C, located on the cells lining the intestine. This is the same receptor that the body's natural peptide uroguanylin acts upon, which is why plecanatide is described as a uroguanylin analog. Stimulating this receptor sets off a chain of intracellular signaling.

The result is increased secretion of chloride and bicarbonate into the intestinal cavity. Water follows these ions into the gut, softening stool and increasing the fluid content of the intestinal contents. This added moisture helps promote more regular bowel movements and can ease the discomfort associated with constipation.

Because the receptor is concentrated in the intestine and the peptide acts mainly there, the effect is largely local to the gut. Some research suggests that signaling along this pathway may also influence the perception of abdominal pain, which is relevant to its use in IBS-C, though the digestive secretory effect is the central mechanism.

Clinical evidence

Plecanatide's approvals are supported by clinical trials in adults with chronic idiopathic constipation and with irritable bowel syndrome with constipation. These studies evaluated whether the medication improved bowel-movement frequency and consistency and, in IBS-C, whether it reduced abdominal discomfort, using standardized response criteria.

The trials compared plecanatide against placebo and assessed both symptom relief and tolerability. Diarrhea emerged as the most commonly reported side effect, which is an expected consequence of a medication that increases intestinal fluid secretion, and it was a primary reason some participants discontinued treatment.

It is worth framing the evidence neutrally. Plecanatide is one of several available options for these conditions, including another guanylate cyclase-C agonist with a similar mechanism. Clinical decisions typically weigh individual response, tolerability, and other treatment factors rather than assuming any single agent is broadly superior.

Dosing & side effects

This article does not provide dosing instructions; plecanatide is a prescription medication taken under the guidance of a healthcare provider. It is formulated as an oral tablet, and clinicians determine its appropriateness based on a patient's condition and history.

The most common side effect is diarrhea, which can sometimes be severe. Because of this, the medication carries important safety considerations, and patients are generally advised to stop and seek guidance if significant diarrhea occurs. Other digestive symptoms have also been reported.

Plecanatide carries a notable contraindication in children. It should not be used in patients younger than a certain age because of a risk of serious dehydration observed in young animals, and it is contraindicated in pediatric patients in the youngest age range. This pediatric warning is a defining safety feature of the drug class and underscores that use should always be directed by a clinician.

Legal status

Plecanatide is a prescription medication approved by the U.S. Food and Drug Administration for chronic idiopathic constipation and for irritable bowel syndrome with constipation in adults. It is dispensed through pharmacies and requires a prescription from a licensed healthcare provider.

Because it is a regulated prescription drug, plecanatide is not available over the counter, and it is not intended for self-directed use without medical oversight. Its pediatric contraindication is reflected in its official labeling and prescribing information.

As with all medications, regulatory status and approved indications can differ between countries. Anyone considering this treatment should consult a qualified prescriber and rely on current, region-specific prescribing information rather than general descriptions.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Al-Salama ZT, Syed YY. Plecanatide: First Global Approval. Drugs. 2017. Peer-reviewed study
2. Love BL. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome. Am J Med. 2019. Peer-reviewed study
3. Bassotti G, Usai Satta P, Bellini M. Plecanatide for the treatment of chronic idiopathic constipation in adult patients. Expert Rev Clin Pharmacol. 2019. Peer-reviewed study
4. Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Ther Adv Gastroenterol. 2018. Peer-reviewed study
5. Miner PB. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2020. Peer-reviewed study
6. Bai T, Xu Z, Zhen Y, et al. Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Drugs. 2025. Peer-reviewed study